Nutriband (NTRB) Stock: Buy, Sell, or Hold?
NTRB - Nutriband Inc. Common Stock
$7.36
-0.16 (-2.13%)
▼
5d:
-18.13%
30d:
+69.39%
90d:
+140.52%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Sep 08, 2026
0d
Get Alerted When NTRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NTRB is down 18.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NTRB is down 18.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.89
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$3.66
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NTRB is currently trading at $7.36, which is considered slightly high relative to its 30-day fair value range of $5.05 to $7.83. From a valuation perspective, the stock is trading at a premium (Forward PE: 5.1) compared to its historical average (2.9). At these levels, the market is pricing in 20.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NTRB is in a strong uptrend. Immediate support is located at $6.56, while resistance sits at $9.19.
Market Sentiment: NTRB scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.00 (+103.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NTRB is in a strong uptrend. Immediate support is located at $6.56, while resistance sits at $9.19.
Market Sentiment: NTRB scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.00 (+103.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$5.05 -
$7.83
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
41.9%
All Signals
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 103.8% below Wall St target ($15.00)
- NEUTRAL: Trading at premium valuation - market expects 20.7% growth which is achievable
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.05 -
$7.83
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$6.56
Resistance Level
$9.19
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.08
Wall Street Target
$15.00
(+103.8%)
Revenue Growth (YoY)
-29.7%
Valuation Premium vs History
+20.7% premium
PE vs Historical
5.1 vs 2.9
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+20.7%
(market-implied from PE analysis)
1-Year Target
$8.88
(+21%)
2-Year Target
$10.72
(+46%)
3-Year Target
$12.94
(+76%)
3-Yr Target (if PE normalizes)
(PE: 5→3)
PE COMPRESSION
$7.39
(+1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 02, 2026 5:37 AM ET
Data refreshes hourly during market hours. Next update: 6:37 AM
Data refreshes hourly during market hours. Next update: 6:37 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NTRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 51 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 55 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 45 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$139 | 66 BUY |
